全文获取类型
收费全文 | 2773篇 |
免费 | 190篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 119篇 |
妇产科学 | 40篇 |
基础医学 | 685篇 |
口腔科学 | 81篇 |
临床医学 | 226篇 |
内科学 | 377篇 |
皮肤病学 | 35篇 |
神经病学 | 245篇 |
特种医学 | 186篇 |
外科学 | 318篇 |
综合类 | 83篇 |
一般理论 | 3篇 |
预防医学 | 211篇 |
眼科学 | 34篇 |
药学 | 132篇 |
中国医学 | 10篇 |
肿瘤学 | 196篇 |
出版年
2022年 | 24篇 |
2021年 | 28篇 |
2020年 | 28篇 |
2019年 | 45篇 |
2018年 | 54篇 |
2017年 | 35篇 |
2016年 | 36篇 |
2015年 | 48篇 |
2014年 | 61篇 |
2013年 | 92篇 |
2012年 | 132篇 |
2011年 | 145篇 |
2010年 | 84篇 |
2009年 | 76篇 |
2008年 | 136篇 |
2007年 | 120篇 |
2006年 | 133篇 |
2005年 | 112篇 |
2004年 | 105篇 |
2003年 | 85篇 |
2002年 | 89篇 |
2001年 | 101篇 |
2000年 | 95篇 |
1999年 | 69篇 |
1998年 | 56篇 |
1997年 | 59篇 |
1996年 | 62篇 |
1995年 | 35篇 |
1994年 | 27篇 |
1993年 | 37篇 |
1992年 | 62篇 |
1991年 | 47篇 |
1990年 | 41篇 |
1989年 | 60篇 |
1988年 | 43篇 |
1987年 | 39篇 |
1986年 | 39篇 |
1985年 | 35篇 |
1984年 | 33篇 |
1983年 | 23篇 |
1980年 | 23篇 |
1979年 | 28篇 |
1978年 | 22篇 |
1977年 | 31篇 |
1976年 | 28篇 |
1975年 | 19篇 |
1972年 | 21篇 |
1971年 | 15篇 |
1970年 | 20篇 |
1962年 | 13篇 |
排序方式: 共有2988条查询结果,搜索用时 15 毫秒
41.
Multivariate random length data occur when we observe multiple measurements of a quantitative variable and the variable number of these measurements is also an observed outcome for each experimental unit. For example, for a patient with coronary artery disease, we may observe a number of lesions in that patient's coronary arteries, along with percentage of blockage of each lesion. Barnhart and Sampson first proposed the multiple population model to analyse multivariate random length data without covariates. This paper extends their approach to deal with multiple covariates. We propose a new multiple population regression model with covariates, and discuss the estimation issues. We analyse data from the TYPE II coronary intervention study to illustrate the methodology. 相似文献
42.
Barr DB Barr JR Driskell WJ Hill RH Ashley DL Needham LL Head SL Sampson EJ 《Toxicology and industrial health》1999,15(1-2):168-179
Pesticides are used on a massive scale in the United States. The widespread use of these pesticides has made it virtually impossible for the average person to avoid exposure at some level. Generally, it is believed that low-level exposure to these pesticides does not produce acute toxic effects; however, various cancers and other noncancer health endpoints have been associated with chronic exposure to several groups of pesticides. Therefore, it is imperative that well-designed studies investigate the potential relationship between contemporary pesticide exposure and health effects. For these studies to be accurate, reliable methods for determining individual exposure must be used. Biological monitoring is a useful tool for assessing exposure to some contemporary pesticides. As with any analytical method, biological monitoring entails many difficulties, but, in many instances, they can be overcome by the logical use of available information and information acquired in carefully designed studies. At the Centers for Disease Control and Prevention (CDC), we have acquired extensive experience in the development and application of specific techniques for biological monitoring of a variety of toxicants, including many of the contemporary-use pesticides. We have used these methods to measure the internal dose of pesticides received by people in acute and chronic incidents resulting from both environmental and industrial exposure. Additionally, we have established normative values, or reference ranges, of several pesticides based on measurements of their metabolites in the urine of randomly selected adults in the US population. These data have been successfully used to distinguish overt exposures from 'background' exposure. In this paper, we present several examples of the usefulness of biological monitoring in urine and blood and describe the difficulties involved with developing methods in these matrices. We also present a general strategy, considerations, and recommendations for developing biological monitoring techniques for measuring the internal dose of contemporary-use pesticides. 相似文献
43.
44.
E M Sadeghi L L Weldon P H Kwon E Sampson 《International journal of oral and maxillofacial surgery》1991,20(3):142-143
This unusual cystic lesion was previously described as a lesion that has features of both botryoid odontogenic cyst and mucoepidermoid tumor and later was named as glandular odontogenic cyst. An additional case is reported and its clinicopathologic features described. The name "mucoepidermoid odontogenic cyst" is proposed. 相似文献
45.
Prithi Pal Singh Ivan Dimich Ian Sampson Norman Sonnenklar 《Journal canadien d'anesthésie》1992,39(6):559-562
This is an open randomized study comparing the efficacy and safety of i.v. esmolol and labetalol in the treatment of perioperative hypertension in ambulatory surgery. Twenty-two elderly patients undergoing cataract surgery under local anaesthesia were studied. The main inclusion criteria were development of systolic blood pressure greater than 200 mmHg or diastolic greater than 100 mmHg. Esmolol was given as a bolus 500 micrograms.kg-1 i.v. followed by a maintenance infusion (150-300 micrograms.kg-1.min-1). Labetalol was given as a bolus of 5 mg i.v. followed by 5 mg increments as needed up to a maximum of 1 mg.kg-1. Esmolol and labetalol both produced reductions in systolic and diastolic blood pressure (P less than 0.05) within ten minutes of administration which lasted for at least two hours. Reduction of blood pressure by esmolol was accompanied by a decrease in HR (P less than 0.05). Two patients developed extreme bradycardia (HR less than 50 beats.min-1) and esmolol had to be discontinued. Labetalol, in contrast, induced only a moderate decrease in HR. None of the patients treated with labetalol experienced any prolonged side effects such as orthostatic hypotension. In conclusion, esmolol may produce considerable bradycardia in elderly patients when hypertension is not accompanied by tachycardia. Labetalol was easier to administer in the ambulatory setting and one-tenth the cost of esmolol. 相似文献
46.
47.
Phase II trial of gefitinib in recurrent glioblastoma. 总被引:13,自引:0,他引:13
Jeremy N Rich David A Reardon Terry Peery Jeannette M Dowell Jennifer A Quinn Kara L Penne Carol J Wikstrand Lauren B Van Duyn Janet E Dancey Roger E McLendon James C Kao Timothy T Stenzel B K Ahmed Rasheed Sandra E Tourt-Uhlig James E Herndon James J Vredenburgh John H Sampson Allan H Friedman Darell D Bigner Henry S Friedman 《Journal of clinical oncology》2004,22(1):133-142
PURPOSE: To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. PATIENTS AND METHODS: This was an open-label, single-center phase II trial. Fifty-seven patients with first recurrence of a glioblastoma who were previously treated with surgical resection, radiation, and usually chemotherapy underwent an open biopsy or resection at evaluation for confirmation of tumor recurrence. Each patient initially received 500 mg of gefitinib orally once daily; dose escalation to 750 mg then 1,000 mg, if a patient received enzyme-inducing antiepileptic drugs or dexamethasone, was allowed within each patient. RESULTS: Although no objective tumor responses were seen among the 53 assessable patients, only 21% of patients (11 of 53 patients) had measurable disease at treatment initiation. Seventeen percent of patients (nine of 53 patients) underwent at least six 4-week cycles, and the 6-month event-free survival (EFS) was 13% (seven of 53 patients). The median EFS time was 8.1 weeks, and the median overall survival (OS) time from treatment initiation was 39.4 weeks. Adverse events were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Drug-related toxicities were more frequent at higher doses. Withdrawal caused by drug-related adverse events occurred in 6% of patients (three of 53 patients). Although the presence of diarrhea positively predicted favorable OS from treatment initiation, epidermal growth factor receptor expression did not correlate with either EFS or OS. CONCLUSION: Gefitinib is well tolerated and has activity in patients with recurrent glioblastoma. Further study of this agent at higher doses is warranted. 相似文献
48.
Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. 总被引:3,自引:0,他引:3
Peter M Grossi Hidenobu Ochiai Gary E Archer Roger E McLendon Michael R Zalutsky Allan H Friedman Henry S Friedman Darell D Bigner John H Sampson 《Clinical cancer research》2003,9(15):5514-5520
PURPOSE: The monoclonal antibody (MAb) trastuzumab (Herceptin) effectively treats HER2-overexpressing extracerebral breast neoplasms. Delivery of such macromolecule therapeutic agents to intracerebral metastases, however, is limited by the tight junctions characteristic of the cerebral vasculature. Direct intracerebral microinfusion (ICM) is a technique that bypasses this blood-brain barrier and allows for a greater delivery of drugs directly into intracerebral tumors. EXPERIMENTAL DESIGN: A human breast cancer cell line transfected to overexpress HER2, MCF-7/HER2-18, was transplanted into the cerebrum of athymic rats. Saline, trastuzumab, or an isotype-matched control MAb was delivered systemically or by ICM to assess toxicity and efficacy. RESULTS: No clinical or histological toxicity related to trastuzumab was evident under any of the conditions studied. Delivery of trastuzumab (2 mg/kg) i.p. led to a median survival of 26.5 days, whereas treatment with trastuzumab (2 mg/kg) by ICM increased the median survival by 96% to 52 days, with two of nine rats surviving >120 days (P = 0.009). Treatment with an isotype-matched control MAb (16 mg/kg) resulted in a median survival of 21 days, which did not differ significantly from the survival of rats treated by ICM with saline (16 days; P = 0.42). Treatment by ICM with trastuzumab (16 mg/kg) led to a median survival of 45 days, with 2 of 10 rats surviving >120 days. These results represent 181% and 114% increases in median survival over the saline and MAb controls, respectively (P < 0.001). CONCLUSION: ICM of trastuzumab is safe and superior to systemic delivery as therapy for HER2-overexpressing intracerebral neoplasms in an athymic rat model. 相似文献
49.
Localization of the tandem pore domain K+ channel TASK-1 in the rat central nervous system 总被引:3,自引:0,他引:3
Kindler CH Pietruck C Yost CS Sampson ER Gray AT 《Brain research. Molecular brain research》2000,80(1):99-108
Recently, a new family of potassium channels with two pore domains in tandem and four transmembrane segments has been identified. Seven functional mammalian channels have been reported at this time. These channels give rise to baseline potassium currents because they are not gated by voltage and exhibit spontaneous activity at all membrane potentials. Although the physiological role of these ion channels has yet to be determined, three mammalian members of this family (TREK-1, TASK-1, TASK-2) are activated by volatile anesthetics and may therefore contribute to the central nervous system (CNS) depression produced by volatile anesthetics. In this study we used northern blot analysis and immunohistochemical localization to determine the expression of TASK-1 subunits in the CNS. TASK-1 immunoreactivity was prominently found in astrocytes of the hippocampus, in the median eminence, in the choroid plexus, and the granular layer, Purkinje cell layer, and molecular layer of the cerebellum. In the spinal cord, strong TASK-I immunoreactivity was seen in ependymal cells lining the central canal and in white matter. These findings suggest a role for the TASK-1 channel in the production of cerebrospinal fluid and function of hypothalamic neurosecretory cells. 相似文献
50.
Michael Weller Nicholas Butowski David D Tran Lawrence D Recht Michael Lim Hal Hirte Lynn Ashby Laszlo Mechtler Samuel A Goldlust Fabio Iwamoto Jan Drappatz Donald M ORourke Mark Wong Mark G Hamilton Gaetano Finocchiaro James Perry Wolfgang Wick Jennifer Green John H Sampson 《The lancet oncology》2017,18(12):e709-e710